Login to Your Account

Earnings Roundup

Regeneron's Revenues Nearly Triple; Eylea Launch Still Strong

By Catherine Shaffer
Staff Writer

Thursday, July 26, 2012
A strong launch of Eylea (aflibercept injection) for age-related macular degeneration led Regeneron Pharmaceuticals Inc.'s revenues for the second quarter, with $194 million in sales.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription